C0737
Cilostazol
≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder
别名:
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H27N5O2
化学文摘社编号:
分子量:
369.46
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Cilostazol, ≥98% (HPLC), powder
SMILES string
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: 10 mg/mL, clear
originator
Otsuka Pharma
Quality Level
Gene Information
human ... PDE3A(5139), PDE3B(5140)
正在寻找类似产品? 访问 产品对比指南
General description
Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.
Application
Cilostazol has been used:
- to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
- in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
- to induce adenosine triphosphate (ATP) release in white adipocytes
Biochem/physiol Actions
Phosphodiesterase III (PDE3) inhibitor
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells
Munoz B, et al.
European Journal of Pharmacology, 616(1-3), 22-30 (2009)
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial
Dawson DL, et al.
Circulation, 98(7), 678-686 (1998)
商品
Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持